Citi lowered the firm’s price target on PTC (PTC) to $195 from $200 and keeps a Neutral rating on the shares ahead of the earnings report. The ...

Engineering and design software provider PTC (NASDAQ:PTC) will be reporting earnings tomorrow afternoon. Here’s what to ...

PTC PTC underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

PTC Therapeutics, Inc. (NASDAQ:PTCT), a biopharmaceutical company focused on developing and commercializing novel medicines for rare disorders, finds itself at a critical juncture. With a promising ...

Barclays analyst Saket Kalia maintained a Buy rating on PTC (PTC – Research Report) today and set a price target of $215.00. The company’s ...

Shares of PTC Inc. PTC advanced 1.30% to $190.93 Tuesday, on what proved to be an all-around great trading session for the ...

Over the past month, PTC Inc. PTC stock increased by 5.53%, and in the past year, by 8.06%. With performance like this, ...

PTC Inc. closed 5.46% short of its 52-week high of $203.09, which the company achieved on December 12th.

在汽车技术日新月异的时代，位于芜湖的惠成电子科技股份有限公司近日宣布成功取得了一项革命性专利——一种一体式汽车PTC控制器，该专利于2023年11月申请，并于2025年2月4日获得国家知识产权局的授权。此项专利不仅展示了惠成电子在汽车制造领域的技术创新，更强调了其在结构牢固性和成本节约上的显著优势。

金融界 2025 年 2 月 4 日消息，国家知识产权局信息显示，芜湖惠成电子科技股份有限公司取得一项名为“一种一体式汽车 PTC 控制器”的专利，授权公告号 CN 222424376 U，申请日期为 2023 年 11 月。

周一，Cantor Fitzgerald的分析师对PTC Therapeutics (NASDAQ: PTCT )表现出积极看法，将目标价从之前的76.00美元上调至113.00美元。该公司维持对该股票的超配评级。根据 InvestingPro 数据，该股票在过去一年中实现了82%的回报率，分析师目标价范围从32美元到76美元不等。此次上调伴随着对公司财务状况和前景的详细分析。

【金融界2025年1月27日讯】在现代科技迅速发展的进程中，浙江绿萌健康科技股份有限公司凭借其卓越的技术研发能力，再次引起行业的广泛关注。近日，国家知识产权局正式发布公告，浙江绿萌健康科技顺利获得了一项关于“双分区PTC加热器双芯发热线3线3针电路半 ...